Table 2

HRs* (and 95% CIs) for occurrence of primary endpoint† according to the baseline serum Lyso-Gb3 levels and the pretreatment Lyso-Gb3 exposure, both per natural log increase

Baseline Lyso-Gb3 levelsPretreatment exposure to Lyso-Gb3
HR95% CIP valueHR95% CIP value
Crude2.121.32 to 3.420.0023.021.69 to 5.37<0.001
Model 12.451.44 to 4.140.0012.881.58 to 5.250.001
Model 23.751.44 to 9.730.0073.691.60 to 8.510.002
Model 34.621.55 to 13.810.0063.411.11 to 10.490.03
  • *Model 1: adjusted for age at Lyso-Gb3 determination; Model 2: additionally, adjusted for male sex; Model 3: additionally, adjusted for classic phenotype.

  • †Primary endpoint was defined as a composite of first occurrence of renal replacement therapy requirement (kidney transplant or chronic dialysis), new onset of atrial fibrillation, pacemaker and/or implantable cardioverter defibrillator implantation, myocardial infarction, cerebrovascular events (stroke or transient ischaemic attack), death.